Although we did not find the precise mechanism of this phenomenon, further studies are needed to clarify the accrual role of p21 up-regulation to chemosensitivity of cisplatin. chemosensitivity to cisplatin in A549 cells in vitro. Moreover, in vivo experiment showed that saRNA targeting the promoter region of p21 could significantly inhibit A549 xenograft tumor growth. == Conclusions == These results indicate that p21 plays a role in lung cancer drug-resistance process. In addition, this study also provides evidence for the usage of saRNA as a therapeutic option for up-regulating lower-expression genes in lung cancer. == Background == Lung cancer is the most common cause of cancer mortality worldwide. Non-small-cell lung carcinomas (NSCLCs), which represent around 80% of lung tumors, exhibit poor prognosis and are usually resistant to conventional chemotherapy. Cisplatin is one of the GSK429286A most potent anticancer agents, displaying significant clinical activity against a variety of solid tumors. The most effective systemic chemotherapy for non-small cell lung cancer (NSCLC) was cisplatin-based combination treatment. Unfortunately, the outcome of cisplatin therapy on NSCLC seems to be unsatisfactory. The use of cisplatin in cancer chemotherapy is limited by acquired or intrinsic resistance of cells to the drug. The cytotoxicity of cisplatin is believed mainly due to interaction with DNA, forming inter-and intra-strand adducts, hindering both RNA transcription and DNA replication, leading to cell cycle arrest and apoptosis. Numerous cellular mechanisms potentially contributing to clinical cisplatin resistance have been proposed, including changes in cellular drug accumulation, detoxification of the drug, inhibition of apoptosis and GSK429286A restoration of the DNA adducts but the exact mechanisms are still need to be validated. It has been reported that P21 manifestation level is definitely involved in the resistant phenotype of this drug [1-4]. p21WAF1/CIP1 (p21) is definitely a well-characterized cyclin-dependent kinase (cdk) inhibitor that belongs to the Cip/Kip family of cdk inhibitors. It primarily inhibits the activity of cyclin/cdk2 complexes and negatively modulates cell cycle progression [3-6]. Loss or inactivation of p21 is seen clinically GSK429286A in main solid tumors and related with poor prognosis of these tumors [7,8]. Additionally, there is a growing body of evidence suggesting that practical loss of p21 can mediate a drug-resistance phenotype in tumor therapy [9,10]. RNA-induced gene activation is definitely a transcriptional gene activation trend specifically induced by double small RNA (dsRNA) molecule focusing on gene promoter areas. This trend was termed RNAa and the dsRNA molecules were designated small activating RNAs (saRNAs). By focusing on gene promoter areas, saRNAs induce the demethylation of histone, leading to transcriptional gene activation. It has been shown that saRNA could inhibit cell proliferation and viability via up-regulation of p21 and E-cadherin in human being bladder malignancy cells [11-13]. Since saRNAs offer IL23P19 a practical and cost-effective approach to activate gene manifestation, it may be additional method except for ectopic manifestation in enhancing manifestation of targeted genes. In this study, we explored the effect of up-regulation of p21 gene manifestation on drug-resistance in A549 non-small-cell lung carcinoma cells by transfecting the GSK429286A saRNA focusing on the promoter region of p21 into A549 cells. We observed activation of p21 manifestation in A549 lung carcinoma cells after transfection of saRNA. The enhanced p21 manifestation was correlated with a significant growth inhibition and enhancement of chemosensitivity to cisplatin in A549 cells in vitro and vivo. These results provide evidence of an additional restorative strategy for lung malignancy therapy especially for chemoresisitance lung carcinomas. == Methods == == Design and preparation of dsRNA == saRNA focusing on GSK429286A the promoter of p21 at position-322 relative to the transcription start site was termed as dsP21-322 and designed as previously explained [9]. Scramble dsRNA with the following sequence: S, 5′-UUCUCCGAACGUGUCACGU [dT][dT]-3′; AS, 5′-ACGUGACACGUUCGGAGAA[dT][dT]-3′ was also synthesized and used as control. Synthetic dsRNAs were manufactured by Genepharma Inc (Shanghai, China). == Cell tradition and transfection == Human being lung carcinoma cells (A549) were cultured in Dulbecco’s revised Eagle’s medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum and penicillin (100 Devices/ml)/streptomycin(0.1.
